Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

T Cells in CTCL Have an Exhausted Phenotype While Cutaneous Dendritic Cells Display a Normally Activated Mature Phenotype

Christiane Querfeld, MDPhD, Shane A Curran, PhD, Samantha Leung, BS, Patricia L Myskowski, MD, Steven M. Horwitz, MD, Allan C Halpern, MD, James W. Young, MD

Blood (2014) 124 (21): 1695.

https://doi.org/10.1182/blood.V124.21.1695.1695

Published: 2014

Journal Articles

Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.

Janet Y. Li, BA, Melissa Pulitzer, MD, Patricia L. Myskowski, MD, Steven Dusza, Dr.PH, Steven M. Horwitz, MD, Alison Moskowitz, MD, Christiane Querfeld, MD, PhD

Blood (2012) 120 (21): 2643.

https://doi.org/10.1182/blood.V120.21.2643.2643

Published: 2012

Journal Articles

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Matthew A Lunning, DO, Jason Gonsky, MD, PhD, Jia Ruan, MD, PhD, Adrienne A. Phillips, MD, MPH, Melissa Pulitzer, MD, Alison Moskowitz, MD, Christiane Querfeld, MD PhD, Patricia L Myskowski, M.D., Ariela Noy, MD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2735.

https://doi.org/10.1182/blood.V120.21.2735.2735

Published: 2012

Journal Articles

CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.

Matthew A Lunning, DO, April Chiu, M.D., Julie Teruya Feldstein, MD, Jocelyn C. Maragulia, Alison Moskowitz, MD, Matthew J. Matasar, MD, MS, David J. Straus, MD, Ariela Noy, MD, Patricia L Myskowski, M.D., Andrew D. Zelenetz, MD, PhD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2706.

https://doi.org/10.1182/blood.V120.21.2706.2706

Published: 2012

Journal Articles

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Steven M. Horwitz, Youn H. Kim, Francine Foss, Jasmine M. Zain, Patricia L. Myskowski, Mary Jo Lechowicz, David C. Fisher, Andrei R. Shustov, Nancy L. Bartlett, Maria L. Delioukina, Tony Koutsoukos, Michael E. Saunders, Owen A. O'Connor, Madeleine Duvic

Blood (2012) 119 (18): 4115–4122.

https://doi.org/10.1182/blood-2011-11-390211

Published: 2012

NARROW

T Cells in CTCL Have an Exhausted Phenotype While Cutaneous Dendritic Cells Display a Normally Activated Mature Phenotype

Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

T Cells in CTCL Have an Exhausted Phenotype While Cutaneous Dendritic Cells Display a Normally Activated Mature Phenotype

Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center.

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only